Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
about
Selective use of sorafenib in the treatment of thyroid cancerUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Transport of thyroid hormone in brain.Role of monocarboxylate transporters in drug delivery to the brain.Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.Clinical review: kinase inhibitors: adverse effects related to the endocrine system.Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.Thyroid dysfunctions induced by tyrosine kinase inhibitors.VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.Pituitary side effects of old and new drugs.Novel therapies for thyroid cancer.Structure and function of thyroid hormone plasma membrane transporters.Sorafenib for the treatment of thyroid cancer: an updated review.Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.Chemistry and Biology in the Biosynthesis and Action of Thyroid Hormones.Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination.Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs.Membrane-traversing mechanism of thyroid hormone transport by monocarboxylate transporter 8.Chemie und Biologie der Schilddrüsenhormon-Biosynthese und -Wirkung
P2860
Q26752891-15787213-EBFA-4698-AA59-7E49F070F4C1Q33408049-CB26A828-569B-4955-9EAD-288070BBEC85Q33794663-5A3BD7A2-5134-41C5-892F-648D40688B2CQ33854710-28DD9AD2-3C9E-44F5-BA06-088E57AE7A57Q33931413-FF4403BC-38B8-4B29-88B6-E95AC5031043Q36736494-53130057-4E7F-4159-A419-92FD42C680F0Q38071132-4257311E-B4B2-4DEC-B6F5-E5BAA2D5745BQ38211342-C9CF32C3-3317-422F-87F6-016D2107E0B8Q38232368-47A61794-632F-49D3-913E-3E0E92CFDADCQ38234756-C3C880D8-DBFD-45EC-8C24-9EB1E45CC6ECQ38260495-C67EA729-DF52-4434-9980-03B45DBE47DAQ38299941-754B3195-7DE2-413D-AFBC-EE762310793AQ38326036-79DA3241-837A-4804-90DF-CE76D4D331BDQ38625034-937DECA6-8F76-4A99-985C-7D963581C788Q38813874-105A244E-8503-43D2-93F8-AEBDBE4FE4BCQ38844606-5E638D50-8705-499E-BDC4-51986BBCA9C7Q47129278-31EE31C5-3453-4329-894C-8B9F84491E12Q48202305-A6CB85B7-9438-4AAB-BF80-D4047E367E43Q48301403-DFBB452F-CA59-471A-A2EA-91824C1A02ABQ56990425-12B61E73-FB00-486D-84D0-0E852CA9CD3E
P2860
Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Tyrosine kinase inhibitors non ...... iated iodothyronine transport.
@en
Tyrosine kinase inhibitors non ...... iated iodothyronine transport.
@nl
type
label
Tyrosine kinase inhibitors non ...... iated iodothyronine transport.
@en
Tyrosine kinase inhibitors non ...... iated iodothyronine transport.
@nl
prefLabel
Tyrosine kinase inhibitors non ...... iated iodothyronine transport.
@en
Tyrosine kinase inhibitors non ...... iated iodothyronine transport.
@nl
P2093
P356
P1476
Tyrosine kinase inhibitors non ...... iated iodothyronine transport.
@en
P2093
Doreen Braun
Jerome M Hershman
Philipp le Coutre
Theo D Kim
P304
P356
10.1210/JC.2011-1837
P407
P577
2011-10-26T00:00:00Z